Oxford BioTherapeutics Secures Fourth License with Boehringer Ingelheim
Deal News | Jan 13, 2025 | Catapult Ventures Group
In a significant move within the biopharmaceutical industry, Oxford BioTherapeutics (OBT), a clinical-stage oncology company known for its innovative pipeline of immuno-oncology and Antibody Drug Conjugate (ADC) therapies, announced that Boehringer Ingelheim has exercised an option to acquire a fourth license. This development enhances Boehringer Ingelheim's involvement in advancing antibody-based cancer treatments, marking a continued partnership between the two firms. The strategic licensing agreement supports Boehringer Ingelheim's agenda for broadening its oncology treatment options, potentially offering new therapies for cancer patients globally. Oxford BioTherapeutics, headquartered in Oxford, UK with operations in San Jose, California, continues to demonstrate leadership in developing pioneering oncology therapies. Catapult Ventures Group, as an investment firm supporting innovative life sciences advancements, may play a pivotal role in facilitating the ongoing growth and strategic partnerships of Oxford BioTherapeutics.
Sectors
- Biopharmaceuticals
- Oncology
Geography
- United Kingdom – Oxford BioTherapeutics is based in Oxford, UK, making it a primary geographical focus in the article.
- United States – The operations of Oxford BioTherapeutics in San Jose, California, highlight the US as another geographical focus.
Industry
- Biopharmaceuticals – The article is centered around the development and licensing of novel antibody-based cancer treatments, a key area within the biopharmaceutical industry.
- Oncology – The article specifically discusses oncology-focused treatments, highlighting advancements in cancer therapies.
Financials
- – The article does not provide specific financial details regarding the transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Oxford BioTherapeutics | Target company | Company | A clinical-stage oncology company with a strong pipeline in immuno-oncology and ADC therapies. |
| Boehringer Ingelheim | Buyer | Company | A global pharmaceutical company acquiring a license to develop novel cancer treatments. |
| Catapult Ventures Group | PE Firm | Company | An investment firm that supports innovative advancements in life sciences, possibly backing Oxford BioTherapeutics. |